Here, we present the first demonstration of the potent anti-leukemic activity of the histone deacetylase (HDAC) inhibitor martinostat in both TKI-sensitive and TKI-resistant CML. The gene discussed is HDAC9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.